<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00151736</url>
  </required_header>
  <id_info>
    <org_study_id>SDX-101-03</org_study_id>
    <nct_id>NCT00151736</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <official_title>A Randomized, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <brief_summary>
    <textblock>
      This is a Phase 2, multi-center, open label, randomized clinical study to evaluate the safety
      and efficiency of SDX-101 in combination with chlorambucil (CLB) and chlorambucil alone in
      Chronic Lymphocytic Leukaemia (CLL) patients. The study treatment period will be
      approximately 24-26 weeks with a follow-up period of approximately 8 weeks. Following the end
      of treatment, patients with a confirmed complete response, partial response or stable disease
      will be followed for up to 2 years to assess time to disease progression. Approximately 80
      patients with documented diagnosis of B-cell CLL by standard clinical and immunophenotyping
      criteria will be enrolled into the SDX-101-03 study. This study is being conducted in the
      following European countries: France, Germany, Poland, Sweden and the United Kingdom.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Marrow Biopsy or Aspiration</measure>
    <time_frame>Baseline + 6 months</time_frame>
    <description>Overall response rate assessment according to National Cancer Institute-Working Group (NCI-WG) criteria using cytogenetic and biomarker evaluations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytogenetic and biomarker evaluations + adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Cytogenetic and biomarker evaluations performed on day 14 (for regimen B) and day 1 (for regimen A) to assess Safety and Tolerability. Study visits to assess safety occur every 2 weeks for 3 months, then every month thereafter. Safety assessments include: medical history, physical examinations, vital sign measurements, adverse event assessment, routine hematology and serum chemistry tests, urinalysis, and ECGs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Chlorambucil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regime A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-etodolac with chlorambucil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regime B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorambucil</intervention_name>
    <description>Chlorambucil 2mg tablets</description>
    <arm_group_label>Chlorambucil</arm_group_label>
    <other_name>SDX-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-etodolac + chlorambucil</intervention_name>
    <description>R-etodolac 600mg tablets + chlorambucil 2mg tablets</description>
    <arm_group_label>R-etodolac with chlorambucil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of B-cell CLL by standard clinical and immunophenotypic criteria as
             specified by the NCI working group revised guidelines for diagnosis and treatment of
             CLL(32).

          2. Binet stages A-C with evidence of active disease requiring treatment by the presence
             of one or more of the following at the time of study entry:

               -  Disease related B symptoms (Fever &gt; 38C [100.5F] for ≥ 2 weeks without evidence
                  of infection, night sweats without evidence of infection, weight loss &gt; 10%
                  within previous 6 mo.).

               -  Evidence of progressive marrow failure as manifested by:

               -  A decrease in hemoglobin to &lt; 10g/dL, or

               -  A decrease in platelet count to &lt; 100 x 10(9)/L within the previous 6 months, or

               -  A decrease in absolute neutrophil count (ANC) to &lt; 1.0 x 10(9)/L within 6 months

               -  Progressive lymphocytosis with an increase of &gt; 50% over a 2 month period, or an
                  anticipated doubling time of &lt; 6 months.

               -  Massive nodes or clusters(i.e., &gt; 10 cm in longest diameter) or progressive
                  lymphadenopathy.

               -  Progressive splenomegaly to &gt; 2cm below the left costal margin or other
                  organomegaly with progressive increase over 2 consecutive clinical visits ≥ 2
                  weeks apart.

          3. No prior chemotherapy for CLL.

          4. Age ≥ 18 at signing of informed consent.

          5. World Health Organization (WHO) performance status ≤ 0-2 (Appendix B).

          6. Platelet count &gt; 50,000/μL, hemoglobin &gt; 8.0 g/dl and absolute neutrophil count &gt;
             1000/μL.

          7. Renal function ≤ 1.5 x upper limit normal (blood urea nitrogen [BUN], serum
             creatinine)

          8. Liver function ≤ 1.5 times upper limit of normal (total bilirubin, SGOT (AST) and SGPT
             (ALT) values).

          9. Female patients of childbearing potential must have a negative pregnancy test (serum
             or urine Beta-human chorionic gonadotropin, Beta-HCG); men and women of reproductive
             potential must employ effective contraceptive methods while on study therapy, and for
             2 months following completion of treatment.

         10. Signed EC/IRB-approved informed consent by patient prior to all study related
             procedures.

        Exclusion Criteria:

          1. Active autoimmune manifestation of CLL such as ongoing hemolytic anemia or ITP

          2. History of a second malignancy with the exception of cervical cancer,or resected basal
             cell carcinoma or other malignancies with no evidence of recurrence 5 or more years
             since diagnosis.

          3. Chronic viral infection: positive hepatitis B or hepatitis C serology, known positive
             for human immunodeficiency virus (HIV) or human T-leukemia/lymphoma virus (HTLV).

          4. Transformation to an aggressive B-cell malignancy such as Richter's transformation,
             prolymphocytic leukemia (PLL) or large B-cell lymphoma.

          5. Clinical evidence of CNS involvement with CLL.

          6. Serious infection, medical condition, or psychiatric condition that, in the opinion of
             the investigator, might interfere with the achievement of the study objectives.

          7. Treatment with any investigational agent within 4 weeks of study entry.

          8. The use of steroids, nonsteroidal anti-inflammatory drugs, regardless of indication
             (excluding prophylactic use of aspirin for prevention of acute myocardial infarction
             or stroke)

          9. Pregnancy or currently breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chef du Service d'Hematologie Clinique CHU Clemenceau</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service maladies du sang CHRU- rue Michel Polonovski</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Benjamin Franklin Medizinische Klinik III Hämatologie, Onkologie und Transfusionsmedizin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Schwerpunktpraxis</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Poliklinik der Universität Hämatologie/Onkologie</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny AM Klinika Hematologii</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 Akademickie Centrum Kliniczne Akdemii Medycznej w Gdansku Klinika Hematologii</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytet Jagiellonski Collegium Medicum Katedra i Klinika Hematologii</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Klinika Hematologii Instytutu Medycyny Wewnetrznej Uniwersytetu Medycznego w Lodzi</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatna Praktyka Lekarska z Osrodkiem Badan Klinicznych Prof. L. Szczepanskiego</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny Katedra i Klinika Hematologii Onkologii i Chorob Wewnetrznych AM</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum för Hematologi Karolinska Universitetssjukhuset, Solna</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologkliniken Karolinska Universitetssjukhuset, Huddinge</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologkliniken Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematologisektionen Medicincentrum Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital Dept. of Haematology</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiff and Vale NHS Trust University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stobhill Hospital Department of Haematology</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary Department of Haematology</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary Department of Oncology &amp; Haematology</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>June 8, 2012</last_update_submitted>
  <last_update_submitted_qc>June 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>CLL</keyword>
  <keyword>Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorambucil</mesh_term>
    <mesh_term>Etodolac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

